Neo Ivy Capital Management’s Quest Diagnostics DGX Stock Holding History

Neo Ivy Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,910	Closed	-$882K	–	418
2025 Q2	$882K	Buy	+4,910	New	+$853K	0.28%	130
2025 Q1	–	Sell	-24,681	Closed	-$3.72M	–	320
2024 Q4	$3.72M	Buy	+24,681	New	+$3.84M	0.75%	32
2023 Q4	–	Sell	-5,404	Closed	-$659K	–	334
2023 Q3	$659K	Buy	+5,404	New	+$720K	0.29%	112
2022 Q4	–	Sell	-20	Closed	-$2K	–	388
2022 Q3	$2K	Buy	+20	New	+$2.63K	0.01%	358
2022 Q2	–	Sell	-462	Closed	-$64K	–	454
2022 Q1	$64K	Buy	462 +303	+191%	+$42.2K	0.06%	353
2021 Q4	$28K	Sell	159 -1,037	-87%	-$158K	0.04%	339
2021 Q3	$136K	Buy	+1,196	New	+$175K	0.16%	201
2021 Q2	–	Sell	-44	Closed	-$6K	–	487
2021 Q1	$6K	Sell	44 -4,871	-99%	-$600K	0.01%	431
2020 Q4	$586K	Buy	4,915 +4,713	+2,333%	+$575K	0.65%	38
2020 Q3	$23K	Sell	202 -994	-83%	-$117K	0.02%	406
2020 Q2	$136K	Sell	1,196 -753	-39%	-$79.9K	0.16%	201
2020 Q1	$157K	Buy	+1,949	New	+$202K	0.26%	157
2019 Q3	–	Sell	-1,855	Closed	-$189K	–	310
2019 Q2	$189K	Buy	+1,855	New	+$178K	0.11%	209

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Neo Ivy Capital Management's DGX Position: Q3 2025 in Review

Neo Ivy Capital Management sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 4,910 shares — an estimated $882K sold.

Neo Ivy Capital Management first reported a position in DGX in Q2 2019 and held it in 13 quarters. The position peaked at $3.72M in Q4 2024. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

Neo Ivy Capital Management reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
Neo Ivy Capital Management sold 4,910 Quest Diagnostics shares in Q3 2025, an estimated $882K.
Neo Ivy Capital Management first reported a position in Quest Diagnostics in Q2 2019 and held it in 13 quarters.
Neo Ivy Capital Management's Quest Diagnostics position peaked at $3.72M in Q4 2024.
1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Neo Ivy Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.